NCM
VERV

Nantahala Capital Management’s Verve Therapeutics VERV Stock Holding History

Nantahala Capital Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-331,437
Closed -$3.72M – 177
2025
Q2 		$3.72M Buy
+331,437
New +$1.89M 0.15% 104

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Nantahala Capital Management's VERV Position: Q3 2025 in Review

Nantahala Capital Management sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 331,437 shares — an estimated $3.72M sold.

Nantahala Capital Management first reported a position in VERV in Q2 2025 and held it in 1 quarter. The position peaked at $3.72M in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Nantahala Capital Management reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Nantahala Capital Management sold 331,437 Verve Therapeutics shares in Q3 2025, an estimated $3.72M.
  • Nantahala Capital Management first reported a position in Verve Therapeutics in Q2 2025 and held it in 1 quarter.
  • Nantahala Capital Management's Verve Therapeutics position peaked at $3.72M in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Nantahala Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.